Charisma Mylavarapu
Hematology & Oncology · Irvine, CANPI 1477117653
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,713 and has fallen 66.8% since, to $568 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 109 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$489
- Sobi, Inc$353
- AVEO Pharmaceuticals, Inc.$314
- Gilead$190
- Pharmaessentia USA Corporation$190
- Daiichi Sankyo Inc.$135
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,87096%
- Education$1104%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 23 | $489 |
| Sobi, Inc | 13 | $353 |
| AVEO Pharmaceuticals, Inc. | 7 | $314 |
| Gilead | 4 | $190 |
| Pharmaessentia USA Corporation | 6 | $190 |
| Daiichi Sankyo Inc. | 5 | $135 |
| Eisai Inc. | 5 | $127 |
| Merck | 5 | $125 |
| AbbVie | 4 | $104 |
| Regeneron Healthcare Solutions, Inc. | 3 | $91 |
| Novartis | 3 | $72 |
| Blueprint Medicines Corporation | 2 | $58 |
| Taiho Oncology, Inc. | 2 | $58 |
| Puma Biotechnology, Inc. | 2 | $49 |
| Beigene USA, Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Bristol Myers Squibb | 1 | $40 |
| Incyte Corporation | 2 | $39 |
| Tersera Therapeutics LLC | 1 | $38 |
| GSK | 1 | $34 |
| Seagen Inc. | 2 | $34 |
| Beone Medicines USA, Inc. | 1 | $32 |
| Johnson & Johnson | 1 | $32 |
| Genentech USA, Inc. | 1 | $31 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Iovance Biotherapeutics, Inc. | 1 | $27 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Pfizer | 1 | $25 |
| Accord Healthcare, Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Array Biopharma Inc | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Acrotech Biopharma Inc. | 1 | $19 |
| CSL Behring | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trodelvy$125
How this compares
$2,980 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 14 | $44 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Irvine
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.